Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+ and Cholestech LDX point-of-care methods in remote Australian Aboriginal communities

Clinica Chimica Acta

Volumn 367, Issue 1-2, 2006, Pages 69-76

  Shemesh, Tomer ^a,b   Rowley, Kevin G ^c   Shephard, Mark ^d   Piers, Leonard S ^a   O'Dea, Kerin ^a,c  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b CHARLES DARWIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

Aboriginal people; Diabetes; Point of care testing; Risk factor screening

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABORIGINE; ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANALYZER; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; EVALUATION; GEOGRAPHIC PATHOLOGY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; KAPPA STATISTICS; LABORATORY TEST; MASS SCREENING; MICROALBUMINURIA; NONPARAMETRIC TEST; PARAMETRIC TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RELIABILITY; RISK ASSESSMENT; RISK FACTOR; RURAL AREA; RURAL POPULATION; STATISTICAL CONCEPTS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; URBAN AREA; URBAN POPULATION;

ADOLESCENT; ADULT; AGED; ALBUMINS; CHOLESTEROL, HDL; DIAGNOSTIC TESTS, ROUTINE; DISEASE; HEART DISEASES; HUMANS; MASS SCREENING; MIDDLE AGED; OCEANIC ANCESTRY GROUP; POINT-OF-CARE SYSTEMS; RESIDENCE CHARACTERISTICS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 33645815482     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.11.014     Document Type: Article

References (29)

1. Daniel M., Rowley K.G., McDermott R., Mylvaganam A., and O'Dea K. Diabetes incidence in an Australian Aboriginal population. An 8-year follow-up study. Diabetes Care 22 (1999) 1993-1998
2. Australian Institute of Health and Welfare. The Health and Welfare of Australia's Aboriginal and Torres Strait Islander Peoples. Canberra ACT; 2003.
3. Lee A.J., O'Dea K., and Mathews J.D. Apparent dietary intake in remote Aboriginal communities. Aust J Public Health 18 (1994) 190-197
4. O'Dea K. Westernization and non-insulin-dependent diabetes in Australian Aborigines. Ethn Dis 1 (1991) 171-187
5. Cagliero E., Levina E.V., and Nathan D.M. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 22 (1999) 1785-1789
6. Shephard M., Allen G., Bartlett L., et al. Albuminuria in a remote South Australian Aboriginal community: results of a community-based screening program for renal disease. Rural Remote Health (2003). http://www.rrh.deakin.edu.au. (Online) 8 Feb 2003. http://www.rrh.deakin.edu.au.
7. Neil A., Hawkins M., Potok M., Thorogood M., Cohen D., and Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 16 (1993) 996-1003
8. Yudkin J.S., Forrest R.D., and Jackson C.A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington diabetes survey. Lancet 2 (1988) 530-533
9. Shephard M., and Tallis G. Assessment of the point-of-care Cholestech lipid analyser for lipid screening in Aboriginal communities. Aust J Med Sci 23 (2002) 2-10
10. Trinder P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J Clin Pathol 22 (1969) 246
11. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
13. Chaiken R.L., Khawaja R., Bard M., Eckert N., Banerji M.A., and Lebovitz H.E. Utility of untimed urinary albumin measurements in assessing albuminuria in Black NIDDM subjects. Diabetes Care 20 (1997) 709-713
14. American Diabetes Association. Position statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care 25 (2002) 213-229
15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 25 (2002) 5-20
16. Rosner B. Fundamental of biostatistics (1990), PWS-Kent Publishing Company 458
17. Shemesh T., Piers L.S., and O'Dea K. Use of the Bayer DCA 2000+ for the measurement of glycated haemoglobin in a remote Australian Aboriginal community. Ann Clin Biochem 40 (2003) 566-568
18. 1c testing using the Bayer DCA 2000 in Australian Aboriginal community controlled health services. Clin Biochem Rev 24 (2003) 123-131
19. 1c testing-the 'QAAMS' program for Aboriginal health workers. Aborig Islander Health Work J 27 (2003) 12-18
20. 1c and blood glucose in a remote Aboriginal Australian community. Med J Aust 182 (2005) 524-720
21. Shephard M.D., Harris S., and Hoy W. The dilution and quantitation of urine samples with high albumin : creatinine ratio on the Bayer DCA 2000. Clin Biochem Rev 22 (2001) 83
22. Barter P.J., and Rye K.A. High density lipoproteins and coronary heart disease. Atherosclerosis 121 (1996) 1
23. Medical Service Advisory Committee application 1026. Evaluation of Near Patient Cholesterol Testing Using the Cholestech LDX. AusInfo, Canberra, ACT; 2001.
24. Kronenberg F., Lobentanz E.M., Konig P., Utermann G., and Dieplinger H. Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 35 (1994) 1318-1328
25. Shield J.P., Hunt L.P., Morgan J.E., and Pennock C.A. Are frozen urine samples acceptable for estimating albumin excretion in research?. Diabet Med 12 (1995) 713-716
26. 1c testing in a community setting. Diabetes Care 19 (1996) 764-767
27. Shephard M.D., Barratt L.J., and Simpson-Lyttle W. Is the Bayer DCA 2000 acceptable as a screening instrument for the early detection of renal disease?. Ann Clin Biochem 36 (1999) 393-394
28. Shephard M.D.S., and Gill J.P. An innovative Australian point-of-care model for point-of-care urine albumin : creatinine ratio testing that supports diabetes management in indigenous medical services and has international application. Ann Clin Biochem 42 (2005) 208-215
29. National Cholesterol Education Program. Recommendations on lipoprotein measurement from the working group on lipoprotein measurement (1995), U.S. National Institutes of Health